Literature DB >> 16086962

Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1.

Bita Esmaeli1, Dominick Golio, Linda Lubecki, Jaffer Ajani.   

Abstract

PURPOSE: To report canalicular stenosis as a side effect of the new antineoplastic agent S-1.
DESIGN: Interventional case series.
METHODS: Three patients who received S-1 for treatment of gastrointestinal cancer at a tertiary cancer center were evaluated and treated for epiphora.
RESULTS: Two patients were found to have severe canalicular stenosis and nasolacrimal duct blockage after approximately 6 months of S-1 therapy. One patient underwent dacryocystorhinostomy with silicone tube placement on one side and dacryocystorhinostomy and Pyrex glass tube placement on the other side. The other patient declined a surgical intervention. One additional patient with epiphora had punctal stenosis early in the course of S-1 therapy. His epiphora resolved after probing and irrigation and 4 weeks of topical corticosteroid therapy.
CONCLUSIONS: Canalicular and nasolacrimal duct blockage is a previously unreported side effect of S-1 and should be recognized and treated at its earliest possible stage so that complete closure of the canaliculi can be avoided.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086962     DOI: 10.1016/j.ajo.2005.01.052

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  15 in total

1.  Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy.

Authors:  Hiroyuki Tabuse; Hiroya Kashiwagi; Satoshi Hamauchi; Takahiro Tsushima; Akiko Todaka; Tomoya Yokota; Nozomu Machida; Kentaro Yamazaki; Akira Fukutomi; Yusuke Onozawa; Keita Mori; Narikazu Boku; Masao Ichinose; Hirofumi Yasui
Journal:  Gastric Cancer       Date:  2015-09-11       Impact factor: 7.370

2.  Clinical features and treatment outcomes of patients with tearing after chemotherapy.

Authors:  Jinhwan Park; Joohyun Kim; Sehyun Baek
Journal:  Eye (Lond)       Date:  2018-12-10       Impact factor: 3.775

3.  A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1.

Authors:  Hidenaga Kobashi; Kazutaka Kamiya; Kimiya Shimizu
Journal:  Jpn J Ophthalmol       Date:  2011-03-13       Impact factor: 2.447

4.  Effect of topical steroids on recently developed incomplete nasolacrimal duct obstruction: optical coherence tomography study.

Authors:  Min Kyu Yang; Namju Kim; Ho-Kyung Choung; Sang In Khwarg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-24       Impact factor: 3.117

5.  Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug.

Authors:  Tsugihisa Sasaki; Hiroaki Miyashita; Tamon Miyanaga; Katsushi Yamamoto; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2012-03-13       Impact factor: 2.447

6.  Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.

Authors:  J J Khong; J Muecke
Journal:  Br J Ophthalmol       Date:  2006-05-03       Impact factor: 4.638

Review 7.  [Topical Mitomycin C as a therapy of conjunctival tumours].

Authors:  M Schallenberg; N Niederdräing; K-P Steuhl; D Meller
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

8.  Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1.

Authors:  Yoko Akune; Masakazu Yamada; Chika Shigeyasu
Journal:  Jpn J Ophthalmol       Date:  2018-06-21       Impact factor: 2.447

9.  Predictive factors for ocular complications caused by anticancer drug S-1.

Authors:  Rika Yamada; Chie Sotozono; Takahiro Nakamura; Akihiro Nishida; Shinya Nakanishi; Masaki Hirabatake; Akihito Tsuji; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2016-02-03       Impact factor: 2.447

10.  Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen.

Authors:  A Karamitsos; V Kokkas; A Goulas; P Paraskevopoulos; K Gougoulias; V Karampatakis; K Boboridis
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.